The effects of these CASP7 polymorphisms on NSCLC survival were further evaluated in subgroup analysis by stage, histologic type, sex, and smoking status (Fig 2, ). The variant G-allele carriers of rs4353229 exhibited significantly increased survival (19.7, 21.4, 18.8, and 18.8 months; adjusted P = .008, 0.001, 0.005, and 0.004, respectively), compared with the wild-type homozygous A/A carriers (15.0, 16.5, 15.0, and 14.7 months, respectively) in subgroups of stage IV patients, patients with adenocarcinoma, men, and ever smokers, respectively. Consistent effects were found for variants of rs12415607 in patients with adenocarcinoma and stage IV patients (adjusted P = .002 and 0.014, respectively). On the other hand, the median PFS of patients with the variant A genotypes of rs1127687 was shorter than that of patients with the wild-type G/G genotype in patients with adenocarcinoma, stage IV patients, nonsmokers, and women (adjusted P = .004, 0.019, 0.002, and 0.010, respectively). Statistically significant differences were also observed in other subgroups: for example, an association between the rs11196445 polymorphism and PFS was observed in stage IV patients (adjusted P = 4.0 × 10−4; HR, 1.60; 95% CI, 1.24-2.08).